CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test. The firm operates through two segments: Post-Transplant and Pre-Transplant. The Post-Transplant segment is engages in development of diagnostic solutions for transplant patients. The Pre-Transplant segment develops, manufactures, markets and sells products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
Previous Symbol
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio0.30
Current Ratio2.65
Quick Ratio2.36
Price-To-Earnings
Trailing P/E Ratio-35.64
Forward P/E Ratio-20.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales22.09
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.21) per share
Price / Book-130.67
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-113.89%
Return on Equity-125.24%
Return on Assets-37.81%
Miscellaneous
Employees179
Outstanding Shares38,900,000
Market Cap$1.07 billion
OptionableOptionable
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) released its quarterly earnings data on Thursday, November, 8th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.42. The firm had revenue of $21.18 million for the quarter, compared to analyst estimates of $18.47 million. CareDx had a negative net margin of 113.89% and a negative return on equity of 125.24%. View CareDx's Earnings History.
When is CareDx's next earnings date?
What guidance has CareDx issued on next quarter's earnings?
CareDx updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $74-75 million, compared to the consensus revenue estimate of $69 million.
What price target have analysts set for CDNA?
4 equities research analysts have issued 1 year target prices for CareDx's stock. Their predictions range from $28.00 to $42.00. On average, they anticipate CareDx's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 27.6% from the stock's current price. View Analyst Price Targets for CareDx.
What is the consensus analysts' recommendation for CareDx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (11/6/2018)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $790M, which includes a discounted cash flow analysis based asset value of $803M for pre- and post-transplant tests, using a 15% discount rate and 2% terminal growth rate, excluding $13M debt and assuming 36.5M shares outstanding at the end of 3Q19." (9/18/2018)
Has CareDx been receiving favorable news coverage?
Press coverage about CDNA stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CareDx earned a news impact score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Guardant Health (GH), Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Fulgent Genetics (FLGT), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and CBA Florida (CBAI).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Peter K. Maag, Chief Executive Officer & Director
- Reginald Seeto, President & Chief Business Officer
- Michael Bell, Chief Financial Officer
- James P. Yee, Chief Medical Officer & Executive Vice President
- Anders Eric Karlsson, Chief International Business Officer
Who are CareDx's major shareholders?
CareDx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.41%), Vanguard Group Inc. (4.37%), Vanguard Group Inc (4.37%), Gagnon Securities LLC (4.03%), Credit Suisse AG (3.20%) and Peregrine Capital Management LLC (1.63%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Royce & Associates LP, Perceptive Advisors LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., Bridgeway Capital Management Inc., EAM Investors LLC and EAM Global Investors LLC. Company insiders that have sold CareDx company stock in the last year include Michael Brian Bell, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vanguard Group Inc, Vanguard Group Inc., Bellevue Group AG, Teachers Advisors LLC, Morgan Stanley, Wells Fargo & Company MN and Castleark Management LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $27.44.
How big of a company is CareDx?
CareDx has a market capitalization of $1.07 billion and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
What is CareDx's official website?
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (NASDAQ CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
